Becoming a father seems to make a man less likely to die young. What’s more, when a father passes away within the first five years of his child’s life, the cause is usually non-natural and thus preventable.
Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.
Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.
Is portable MRI suitable for finding abnormalities in the brains of patients receiving new amyloid-targeting therapy for Alzheimer’s disease? Clinical researchers are about to find out.
Alexander Fanaroff, MD, said the late-breaking BE ACTIVE clinical trial presented at ACC.24 offers a blueprint for how to get patients to be more physically active.
The avian influenza virus H5N1 has only turned up in two humans in the U.S., but its recent spread to dairy cattle has some experts on at least slightly elevated alert.
Finding new ways to avoid intraoperative anemia could go a long way toward improving outcomes for female CABG patients. The full analysis, based on more than 1.4 million patients, was published in the Journal of the American College of Cardiology.
ACC.24, the American College of Cardiology's annual meeting in Atlanta, featured the latest in cardiovascular research and technologies. Representatives from Cardiovascular Business were there in person to take in the excitement.
A study out of China found most patients biopsied for prostate lesions did not have clinically significant cancer, calling the clinical ranking systems into question.
Gregg Stone, MD, explains the details of the late-breaking RELIEVE-HF trial at ACC.24, where an inter-atrial shunt improved symptoms in HFrEF, but not in HFpEF patients.
